select a format

Single User License
USD 2000 INR 129700
Site License
USD 4000 INR 259400
Corporate User License
USD 6000 INR 389100

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Dyslipidemia-Pipeline Review, H1 2017

Dyslipidemia-Pipeline Review, H1 2017


  • Products Id :- GMDHC9091IDB
  • |
  • Pages: 280
  • |
  • March 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Dyslipidemia-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia-Pipeline Review, H1 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 17, 19, 14, 4, 41 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 10

Global Markets Direct Report Coverage 10

Dyslipidemia-Overview 11

Dyslipidemia-Therapeutics Development 12

Pipeline Overview 12

Pipeline by Companies 13

Pipeline by Universities/Institutes 18

Products under Development by Companies 19

Products under Development by Universities/Institutes 25

Dyslipidemia-Therapeutics Assessment 26

Assessment by Target 26

Assessment by Mechanism of Action 30

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Dyslipidemia-Companies Involved in Therapeutics Development 38

Acasti Pharma Inc 38

Akcea Therapeutics Inc 38

Allergan Plc 39

Amgen Inc 39

Arisaph Pharmaceuticals Inc 40

AstraZeneca Plc 40

BASF SE 41

BCWorld Pharm Co Ltd 41

BioRestorative Therapies Inc 42

Boryung Pharmaceutical Co Ltd 42

Cadila Pharmaceuticals Ltd 43

Cardax Inc 43

Catabasis Pharmaceuticals Inc 44

Celon Pharma SA 44

Cerenis Therapeutics Holding SA 45

Chong Kun Dang Pharmaceutical Corp 45

CJ HealthCare Corp 46

Connexios Life Sciences Pvt Ltd 46

CymaBay Therapeutics Inc 47

Daewoong Pharmaceutical Co Ltd 47

Daiichi Sankyo Company Ltd 48

Eli Lilly and Company 48

Esperion Therapeutics Inc 49

Gemphire Therapeutics Inc 49

Gilead Sciences Inc 50

GlaxoSmithKline Plc 50

Golden Biotechnology Corp 51

HanAll Biopharma Co Ltd 51

Hanmi Pharmaceuticals Co Ltd 52

Huons Co Ltd 52

Hyundai Pharmaceutical Co Ltd 53

Innovent Biologics Inc 53

IPCA Laboratories Ltd 54

Jeil Pharmaceutical Co Ltd 54

Jenrin Discovery Inc 55

JW Pharmaceutical Corp 55

Kissei Pharmaceutical Co Ltd 56

Kotobuki Pharmaceutical Co Ltd 56

Kowa Company Ltd 57

Kuhnil Pharmaceutical Co Ltd 57

Kyorin Pharmaceutical Co Ltd 58

Lipicard Technologies Ltd 58

Lipigon Pharmaceuticals AB 59

LipimetiX Development Inc 59

Lotus Pharmaceutical Co Ltd 60

Matinas BioPharma Holdings Inc 60

Merck & Co Inc 61

Nippon Chemiphar Co Ltd 61

Omeros Corp 62

Pfizer Inc 62

Pharmena SA 63

Protalix BioTherapeutics Inc 63

Regeneron Pharmaceuticals Inc 64

Samjin Pharmaceutical Co Ltd 64

Sancilio & Company Inc 65

Takeda Pharmaceutical Company Ltd 65

Tasly Pharmaceutical Group Co Ltd 66

Torrent Pharmaceuticals Ltd 66

Yuhan Corp 67

Zydus Cadila Healthcare Ltd 67

Dyslipidemia-Drug Profiles 68

(amlodipine besylate + fimasartan + rosuvastatin calcium)-Drug Profile 68

(amlodipine besylate + olmesartan medoxomil) + rosuvastatin calcium-Drug Profile 69

(amlodipine besylate + rosuvastatin calcium + valsartan)-Drug Profile 70

(amlodipine besylate + rosuvastatin calcium)-Drug Profile 71

(amlodipine besylate + valsartan)+ atorvastatin calcium-Drug Profile 72

(amlodipine maleate + rosuvastatin calcium + telmisartan)-Drug Profile 73

(atorvastatin calcium + choline fenofibrate)-Drug Profile 74

(atorvastatin calcium + hydroxychloroquine sulfate)-Drug Profile 75

(atorvastatin calcium + metformin hydrochloride XR)-Drug Profile 76

(atorvastatin calcium IR + losartan potassium DR)-Drug Profile 77

(candesartan cilexetil + rosuvastatin calcium)-Drug Profile 78

(metformin hydrochloride SR + rosuvastatin calcium)-Drug Profile 79

(metformin hydrochloride SR + rosuvastatin calcium)-Drug Profile 80

(nebivolol hydrochloride + rosuvastatin calcium)-Drug Profile 81

(pitavastatin + valsartan)-Drug Profile 82

4655-K09-Drug Profile 83

AC-261066-Drug Profile 84

AEM-28-Drug Profile 85

AEM-2802-Drug Profile 87

AEM-2814-Drug Profile 88

ALN-AC3-Drug Profile 89

ALN-ANG-Drug Profile 90

AMG-899-Drug Profile 91

anacetrapib-Drug Profile 93

Antibody to Inhibit ANGPTL4 for Hypertriglyceridemia-Drug Profile 95

antroquinonol-Drug Profile 96

ARGX-116-Drug Profile 98

ARI-3037MO-Drug Profile 99

bempedoic acid-Drug Profile 101

bezafibrate SR-Drug Profile 113

BioE-1115-Drug Profile 115

BKC-007-Drug Profile 116

BSN-272-Drug Profile 117

C-3-Drug Profile 118

CAT-2000 Series-Drug Profile 119

CAT-2003-Drug Profile 120

CDR-267F018-Drug Profile 123

CDX-085-Drug Profile 124

centatin-Drug Profile 127

CER-209-Drug Profile 128

CKD-519-Drug Profile 129

CNX-013B2-Drug Profile 131

DF-461-Drug Profile 132

Drugs to Inhibit Sortilin for Hypercholesterolemia-Drug Profile 133

DS-9001-Drug Profile 134

DWJ-1330-Drug Profile 136

etanercept biosimilar-Drug Profile 137

evinacumab-Drug Profile 139

gemcabene calcium-Drug Profile 141

GSK-2041706-Drug Profile 145

HCP-1105-Drug Profile 146

HOB-071-Drug Profile 147

HU-012-Drug Profile 148

IBI-306-Drug Profile 149

icosabutate-Drug Profile 150

IMMH-007-Drug Profile 152

IONIS-ANGPTL3LRx-Drug Profile 153

IONIS-APOCIIILRX-Drug Profile 155

JD-2000 Series-Drug Profile 156

JD-5000 Series-Drug Profile 157

JD-5006-Drug Profile 158

JD-5037-Drug Profile 159

JD-6000 Series-Drug Profile 160

JS-002-Drug Profile 161

K-312-Drug Profile 162

KI-1107-Drug Profile 163

KKM-1201-Drug Profile 164

KT-6971-Drug Profile 165

KTA-439-Drug Profile 166

leucine + niacin-Drug Profile 167

liothyronine sodium-Drug Profile 168

LP-071-Drug Profile 169

LT-5421-Drug Profile 170

LT-5423-Drug Profile 171

LTPO-3FA-Drug Profile 172

LY-3202328-Drug Profile 173

MAT-9001-Drug Profile 174

metformin hydrochloride + rosuvastatin calcium-Drug Profile 176

MN-002-Drug Profile 177

NC-2400-Drug Profile 179

ND-630-Drug Profile 180

ND-654-Drug Profile 182

NKPL-66-Drug Profile 185

Oligonucleotide for Hyperlipidemia and Atherosclerosis-Drug Profile 190

omega-3-carboxylic acids-Drug Profile 191

pemafibrate-Drug Profile 196

peroxibrate-Drug Profile 199

PF-06427878-Drug Profile 200

Protein for Dislipidemia, Obesity and Type 2 Diabetes-Drug Profile 201

Recombinant ApoE4 for Dyslipidemia-Drug Profile 202

REGN-1001-Drug Profile 203

saroglitazar-Drug Profile 204

SC-401-Drug Profile 207

seladelpar-Drug Profile 208

SJP-1603-Drug Profile 212

Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes-Drug Profile 213

Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes-Drug Profile 214

Small Molecule for Atherosclerosis and Hyperlipidemia-Drug Profile 215

Small Molecule for Cardiovascular and Metabolic Diseases-Drug Profile 216

Small Molecule for Hypertriglyceridaemia-Drug Profile 217

Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia-Drug Profile 218

Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia-Drug Profile 219

Small Molecule to Agonize TR-Beta for Dyslipidemia-Drug Profile 220

Small Molecule to Antagonize Farnesoid X Receptor for Dyslipidemia-Drug Profile 221

Small Molecule to Inhibit DGAT-2 for Dyslipidemia and Non-Alcoholic Steatohepatitis-Drug Profile 222

Small Molecule to Inhibit HSL for Dyslipidemia-Drug Profile 223

Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia-Drug Profile 224

Small Molecules to Inhibit FABP1 for Hyperlipidemia and Fatty Liver Disease-Drug Profile 225

Small Molecules to Target GPR146 for Metabolic Disorders-Drug Profile 226

SPX-8522876-Drug Profile 227

Stem Cell Therapy for Hypertension, Hyperlipidemia, Obesity and Type 2 Diabetes-Drug Profile 228

Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease-Drug Profile 230

Synthetic Peptides for Dyslipidemic and Vascular Disorders-Drug Profile 231

TRC-210258-Drug Profile 232

TRIA-662-Drug Profile 233

TSL-1516-Drug Profile 235

volanesorsen sodium-Drug Profile 236

ZLN-005-Drug Profile 243

ZLN-024-Drug Profile 244

ZYH-7-Drug Profile 245

Dyslipidemia-Dormant Projects 246

Dyslipidemia-Discontinued Products 255

Dyslipidemia-Product Development Milestones 259

Featured News & Press Releases 259

Appendix 271

Methodology 271

Coverage 271

Secondary Research 271

Primary Research 271

Expert Panel Validation 271

Contact Us 271

Disclaimer 272

List of Figures

Number of Products under Development for Dyslipidemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Dyslipidemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Dyslipidemia-Pipeline by Acasti Pharma Inc, H1 2017

Dyslipidemia-Pipeline by Akcea Therapeutics Inc, H1 2017

Dyslipidemia-Pipeline by Allergan Plc, H1 2017

Dyslipidemia-Pipeline by Amgen Inc, H1 2017

Dyslipidemia-Pipeline by Arisaph Pharmaceuticals Inc, H1 2017

Dyslipidemia-Pipeline by AstraZeneca Plc, H1 2017

Dyslipidemia-Pipeline by BASF SE, H1 2017

Dyslipidemia-Pipeline by BCWorld Pharm Co Ltd, H1 2017

Dyslipidemia-Pipeline by BioRestorative Therapies Inc, H1 2017

Dyslipidemia-Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017

Dyslipidemia-Pipeline by Cadila Pharmaceuticals Ltd, H1 2017

Dyslipidemia-Pipeline by Cardax Inc, H1 2017

Dyslipidemia-Pipeline by Catabasis Pharmaceuticals Inc, H1 2017

Dyslipidemia-Pipeline by Celon Pharma SA, H1 2017

Dyslipidemia-Pipeline by Cerenis Therapeutics Holding SA, H1 2017

Dyslipidemia-Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Dyslipidemia-Pipeline by CJ HealthCare Corp, H1 2017

Dyslipidemia-Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017

Dyslipidemia-Pipeline by CymaBay Therapeutics Inc, H1 2017

Dyslipidemia-Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Dyslipidemia-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Dyslipidemia-Pipeline by Eli Lilly and Company, H1 2017

Dyslipidemia-Pipeline by Esperion Therapeutics Inc, H1 2017

Dyslipidemia-Pipeline by Gemphire Therapeutics Inc, H1 2017

Dyslipidemia-Pipeline by Gilead Sciences Inc, H1 2017

Dyslipidemia-Pipeline by GlaxoSmithKline Plc, H1 2017

Dyslipidemia-Pipeline by Golden Biotechnology Corp, H1 2017

Dyslipidemia-Pipeline by HanAll Biopharma Co Ltd, H1 2017

Dyslipidemia-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Dyslipidemia-Pipeline by Huons Co Ltd, H1 2017

Dyslipidemia-Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017

Dyslipidemia-Pipeline by Innovent Biologics Inc, H1 2017

Dyslipidemia-Pipeline by IPCA Laboratories Ltd, H1 2017

Dyslipidemia-Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Dyslipidemia-Pipeline by Jenrin Discovery Inc, H1 2017

Dyslipidemia-Pipeline by JW Pharmaceutical Corp, H1 2017

Dyslipidemia-Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Dyslipidemia-Pipeline by Kotobuki Pharmaceutical Co Ltd, H1 2017

Dyslipidemia-Pipeline by Kowa Company Ltd, H1 2017

Dyslipidemia-Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017

Dyslipidemia-Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Dyslipidemia-Pipeline by Lipicard Technologies Ltd, H1 2017

Dyslipidemia-Pipeline by Lipigon Pharmaceuticals AB, H1 2017

Dyslipidemia-Pipeline by LipimetiX Development Inc, H1 2017

Dyslipidemia-Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017

Dyslipidemia-Pipeline by Matinas BioPharma Holdings Inc, H1 2017

Dyslipidemia-Pipeline by Merck & Co Inc, H1 2017

Dyslipidemia-Pipeline by Nippon Chemiphar Co Ltd, H1 2017

Dyslipidemia-Pipeline by Omeros Corp, H1 2017

Dyslipidemia-Pipeline by Pfizer Inc, H1 2017

Dyslipidemia-Pipeline by Pharmena SA, H1 2017

Dyslipidemia-Pipeline by Protalix BioTherapeutics Inc, H1 2017

Dyslipidemia-Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Dyslipidemia-Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017

Dyslipidemia-Pipeline by Sancilio & Company Inc, H1 2017

Dyslipidemia-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Dyslipidemia-Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017

Dyslipidemia-Pipeline by Torrent Pharmaceuticals Ltd, H1 2017

Dyslipidemia-Pipeline by Yuhan Corp, H1 2017

Dyslipidemia-Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Dyslipidemia-Dormant Projects, H1 2017

Dyslipidemia-Dormant Projects, H1 2017 (Contd..1), H1 2017

Dyslipidemia-Dormant Projects, H1 2017 (Contd..2), H1 2017

Dyslipidemia-Dormant Projects, H1 2017 (Contd..3), H1 2017

Dyslipidemia-Dormant Projects, H1 2017 (Contd..4), H1 2017

Dyslipidemia-Dormant Projects, H1 2017 (Contd..5), H1 2017

Dyslipidemia-Dormant Projects, H1 2017 (Contd..6), H1 2017

Dyslipidemia-Dormant Projects, H1 2017 (Contd..7), H1 2017

Dyslipidemia-Dormant Projects, H1 2017 (Contd..8), H1 2017

Dyslipidemia-Discontinued Products, H1 2017

Dyslipidemia-Discontinued Products, H1 2017 (Contd..1), H1 2017

Dyslipidemia-Discontinued Products, H1 2017 (Contd..2), H1 2017

Dyslipidemia-Discontinued Products, H1 2017 (Contd..3), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acasti Pharma Inc, Akcea Therapeutics Inc, Allergan Plc, Amgen Inc, Arisaph Pharmaceuticals Inc, AstraZeneca Plc, BASF SE, BCWorld Pharm Co Ltd, BioRestorative Therapies Inc, Boryung Pharmaceutical Co Ltd, Cadila Pharmaceuticals Ltd, Cardax Inc, Catabasis Pharmaceuticals Inc, Celon Pharma SA, Cerenis Therapeutics Holding SA, Chong Kun Dang Pharmaceutical Corp, CJ HealthCare Corp, Connexios Life Sciences Pvt Ltd, CymaBay Therapeutics Inc, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Company Ltd, Eli Lilly and Company, Esperion Therapeutics Inc, Gemphire Therapeutics Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Golden Biotechnology Corp, HanAll Biopharma Co Ltd, Hanmi Pharmaceuticals Co Ltd, Huons Co Ltd, Hyundai Pharmaceutical Co Ltd, Innovent Biologics Inc, IPCA Laboratories Ltd, Jeil Pharmaceutical Co Ltd, Jenrin Discovery Inc, JW Pharmaceutical Corp, Kissei Pharmaceutical Co Ltd, Kotobuki Pharmaceutical Co Ltd, Kowa Company Ltd, Kuhnil Pharmaceutical Co Ltd, Kyorin Pharmaceutical Co Ltd, Lipicard Technologies Ltd, Lipigon Pharmaceuticals AB, LipimetiX Development Inc, Lotus Pharmaceutical Co Ltd, Matinas BioPharma Holdings Inc, Merck & Co Inc, Nippon Chemiphar Co Ltd, Omeros Corp, Pfizer Inc, Pharmena SA, Protalix BioTherapeutics Inc, Regeneron Pharmaceuticals Inc, Samjin Pharmaceutical Co Ltd, Sancilio & Company Inc, Takeda Pharmaceutical Company Ltd, Tasly Pharmaceutical Group Co Ltd, Torrent Pharmaceuticals Ltd, Yuhan Corp, Zydus Cadila Healthcare Ltd

Dyslipidemia Therapeutic Products under Development, Key Players in Dyslipidemia Therapeutics, Dyslipidemia Pipeline Overview, Dyslipidemia Pipeline, Dyslipidemia Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com